RC
ENGN icon

Rangeley Capital’s enGene Therapeutics ENGN Stock Holding History

Rangeley Capital’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
+305,102
New +$1.24M 0.48% 55

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Rangeley Capital's ENGN Position: Q2 2026 in Review

Rangeley Capital opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 305,102 shares worth $528K. The stake represents 0.48% of the portfolio and ranks #55 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Rangeley Capital held 305,102 shares of enGene Therapeutics worth $528K as of Q2 2026.
  • enGene Therapeutics was a new Rangeley Capital position in Q2 2026.
  • enGene Therapeutics made up 0.48% of Rangeley Capital's portfolio in Q2 2026, its #55 holding.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.